HealthResJ, health, medicine, nursing, research https://ejournals.epublishing.ekt.gr/index.php/HealthResJ/sitemap

Application of the high-flow nasal cannula in patients with acute respiratory distress syndrome


Published: Jul 7, 2025
Keywords:
Acute respiratory distress syndrome high-flow nasal cannula
Evgegia Stergiopoulou
Pavlatou Niki
Abstract

Background: Acute respiratory distress syndrome (ARDS) is an acute inflammatory pulmonary process, which leads to protein-rich non-hydrostatic pulmonary oedema. It causes persistent hypoxemia, increases lung "stiffness" and impairs the lung's ability to excrete carbon dioxide. With the advent of the COVID-19 pandemic, many patients suffering from ARDS could not avoid falling ill. However, in many cases, the time from the onset of disease symptoms to the development of full-blown ARDS differed from that observed in ARDS caused by other underlying conditions. Based on the available data, ARDS associated with COVID-19 does not appear to exhibit a more rapid or severe progression of lung damage compared to ARDS from other causes.


Treatment approach: Supplemental oxygen therapy is one of the most commonly prescribed interventions used by clinicians when treating hypoxic acute care patients. This supplement often comes in the form of a low-flow nasal cannula (LFNC). The nasal cannula is an open system that provides low flow and low oxygen. Particularly in patients with COVID-19, HFNO has been shown to create a more uniform transmission of pressure and distribution of ventilation in the alveoli, compared to invasive mechanical ventilation.


Results: As a result, the probability of overdistension of open alveoli, together with the opening of closed alveoli, is reduced in a heterogeneous lung affected by SARS-COV-2. In normal breathing, about 1% of the air a person inhales is made up of the air exhaled in the previous breath. The result is that part of the exhaled CO2 is respired. However, the use of high-flow nasal oxygen (HFNO) facilitates the delivery of heated, humidified oxygen at high flow rates, effectively flushing out CO₂ from the anatomical dead space in the trachea and bronchi, thereby enhancing gas exchange. This reduces the anatomical dead space and respiration of CO2, promoting its elimination. Conclusions As a result, HFNO has been shown to be effective in treating hypercapnia-induced respiratory failure. The purpose of the present study is to investigate the therapeutic effect after the application of the high-flow nasal cannula in patients with acute respiratory distress syndrome.

Article Details
  • Section
  • Reviews
Downloads
Download data is not yet available.
References
Kempker JA, Abril MK, Chen Y, Kramer MR, Waller LA, Mar-tin GS. The epidemiology of respiratory failure in the United States 2002–2017: a serial cross-sectional study. Critical Care Explorations. 2020;2(6).
Hendrickson KW, Peltan ID, Brown SM. The epidemiology of acute respiratory distress syndrome before and after coronavirus disease 2019. Critical Care Clinics. 2021;37(4):703-16.
Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM, Aaron JG, Claassen J, Rabbani LE, Hastie J, Hochman BR. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. The lancet. 2020;395(10239):1763-70.
Ozsancak Ugurlu A, Habesoglu MA. Epidemiology of NIV for acute respiratory failure in COPD patients: results from the international surveys vs. the “real world”. COPD: Jour-nal of Chronic Obstructive Pulmonary Disease. 2017;14(4):429-38.
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P. A novel coronavirus from pa-tients with pneumonia in China, 2019. New England jour-nal of medicine. 2020;382(8):727-33.
Gattinoni L, Pesenti A. The concept of “baby lung”. Applied Physiology in Intensive Care Medicine 1: Physiological Notes-Technical Notes-Seminal Studies in Intensive Care. 2012:289-97.
Gattinoni L, Pelosi P, Vitale G, Pesenti A, D'Andrea L, Mascheroni D. Body position changes redistribute lung computed-tomographic density in patients with acute res-piratory failure. Anesthesiology. 1991;74(1):15-23.
Nuckton TJ, Alonso JA, Kallet RH, Daniel BM, Pittet JF, Eisner MD, Matthay MA. Pulmonary dead-space fraction as a risk factor for death in the acute respiratory distress syn-drome. NewEngland Journal of Medicine. 2002;346(17):1281-6.
Adhikari NK, Fowler RA, Bhagwanjee S, Rubenfeld GD. Critical care and the global burden of critical illness in adults. The Lancet. 2010;376(9749):1339-46.
Manzano F, Yuste E, Colmenero M, Aranda A, García-Horcajadas A, Rivera R, Fernández-Mondéjar E, Granada Respiratory Failure Study Group. Incidence of acute res-piratory distress syndrome and its relation to age. Journal of critical care. 2005;20(3):274-80.
De Hemptinne Q, Remmelink M, Brimioulle S, Salmon I, Vincent JL. ARDS: a clinicopathologicalconfrontation. Chest. 2009;135(4):944-9.
Guerin C, Bayle F, Leray V, Debord S, Stoian A, Yonis H, Roudaut JB, Bourdin G, Devouassoux-Shisheboran M, Bucher E, Ayzac L. Open lung biopsy in nonresolving ARDS frequently identifies diffuse alveolar damage regardless of the severity stage and may have implications for patient management. Intensivecaremedicine. 2015; 41: 222-30.
Cardinal-Fernández P, Bajwa EK, Dominguez-Calvo A, Menéndez JM, Papazian L, Thompson BT. The presence of diffuse alveolar damage on open lung biopsy is associated with mortality in patients with acute respiratory distress syndrome: a systematic review and meta-analysis. Chest. 2016;149(5):1155-64.
Ware LB, Matthay MA. The acute respiratory distress syn-drome. New England Journal of Medicine. 2000;342(18):1334-49.
Gajic O, Dabbagh O, Park PK, Adesanya A, Chang SY, Hou P, Anderson III H, Hoth JJ, Mikkelsen ME, Gentile NT, Gong MN. Early identification of patients at risk of acute lung in-jury: evaluation of lung injury prediction score in a multi-center cohort study. American journal of respiratory and criticalcaremedicine. 2011;183(4):462-70.
Gorman EA, O’Kane CM, McAuley DF. Acute respiratory distress syndrome in adults: diagnosis, outcomes, long-term sequelae, and management. The Lancet. 2022;400(10358):1157-70.
Zakynthinos, S., & Vrettou, C. (2015). Intensive Care Issues. Kallipos. Open Academic Publications.
Brun-Buisson C, Minelli C, Bertolini G, Brazzi L, Pimentel J, Lewandowski K, Bion J, Romand JA, Villar J, Thorsteinsson A, Damas P. Epidemiology and outcome of acute lung inju-ry in European intensive care units: results from the ALIVE study. Intensive care medicine. 2004; 30:51-61.
Linko R, Okkonen M, Pettilä V, Perttilä J, Parviainen I, Ru-okonen E, Tenhunen J, Ala-Kokko T, Varpula T, FINNALI-Study Group. Acute respiratory failure in intensive care units. FINNALI: a prospective cohort study. Intensive care medicine. 2009;35: 1352-61.
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P. A novel coronavirus from pa-tients with pneumonia in China, 2019. New England jour-nal of medicine. 2020;382(8):727-33.
Villar J, Ferrando C, Martínez D, Ambrós A, Muñoz T, Soler JA, Aguilar G, Alba F, González-Higueras E, Conesa LA, Martín-Rodríguez C. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, ran-domised controlled trial. The LancetRespiratoryMedicine. 2020;8(3):267-76.
Fan E, Brodie D, Slutsky AS. Acute respiratory distress syn-drome: advances in diagnosis and treatment. Jama. 2018;319(7):698-710.
Matthay MA, Thompson BT, Ware LB. The Berlin definition of acute respiratory distress syndrome: should patients re-ceiving high-flow nasal oxygen be included?. The Lancet Respiratory Medicine. 2021;9(8):933-6.
Mündel T, Feng S, Tatkov S, Schneider H. Mechanisms of nasal high flow on ventilation during wakefulness and sleep. Journal of applied physiology. 2013;114(8):1058-65.
Parke RL, Bloch A, McGuinness SP. Effect of very-high-flow nasal therapy on airway pressure and end-expiratory lung impedance in healthy volunteers. Respiratory care. 2015;60(10):1397-403.
Di Mussi R, Spadaro S, Stripoli T, Volta CA, Trerotoli P, Pierucci P, Staffieri F, Bruno F, Camporota L, Grasso S. High-flow nasal cannula oxygen therapy decreases postex-tubation neuroventilatory drive and work of breathing in patients with chronic obstructive pulmonary disease. Criti-cal Care. 2018;22: 1-1.
Frat JP, Thille AW, Mercat A, Girault C, Ragot S, Perbet S, Prat G, Boulain T, Morawiec E, Cottereau A, Devaquet J. High-flow oxygen through nasal cannula in acute hypox-emic respiratory failure. New England Journal of Medicine. 2015;372(23):2185-96.
Rochwerg B, Granton D, Wang DX, Helviz Y, Einav S, Frat JP, Mekontso-Dessap A, Schreiber A, Azoulay E, Mercat A, Demoule A. High flow nasal cannula compared with con-ventional oxygen therapy for acute hypoxemic respiratory failure: a systematic review and meta-analysis. Intensive care medicine. 2019;45: 563-72.
Rochwerg B, Einav S, Chaudhuri D, Mancebo J, Mauri T, Helviz Y, Goligher EC, Jaber S, Ricard JD, Rittayamai N, Roca O. The role for high flow nasal cannula as a respiratory support strategy in adults: a clinical practice guideline. In-tensive care medicine. 2020;46: 2226-37.
Mauri T, Wang YM, Dalla Corte F, Corcione N, Spinelli E, Pesenti A. Nasal high flow: physiology, efficacy and safety in the acute care setting, a narrative review. Open access emergency medicine. 2019:109-20.
Papazian L, Corley A, Hess D, Fraser JF, Frat JP, Guitton C, Jaber S, Maggiore SM, Nava S, Rello J, Ricard JD. Use of high-flow nasal cannula oxygenation in ICU adults: a nar-rative review. Intensive care medicine. 2016;42: 1336-49.
Rengasamy S, Nassef B, Bilotta F, Pugliese F, Nozari A, Ortega R. Administration of supplemental oxygen. The New England journal of medicine. 2021;385(3): e9.
Helviz Y, Einav S. A systematic review of the high-flow nasal cannula for adult patients. Annual Update in Inten-sive Care and Emergency Medicine 2018. 2018:177-91.
Nishimura M. High-flow nasal cannula oxygen therapy in adults: physiological benefits, indication, clinical benefits, and adverse effects. Respiratory care. 2016;61(4):529-41.
Mattioli MI, Escalier N, Díaz-Lobato S. Role of high-flow nasal cannula therapy in the respiratory distress: is it time to change the strategy?. Lung Breath J. 2018;2:1.
Mauri T, Turrini C, Eronia N, Grasselli G, Volta CA, Bellani G, Pesenti A. Physiologic effects of high-flow nasal cannula in acute hypoxemic respiratory failure. American journal of respiratory and critical care medicine. 2017;195(9):1207-15.
Renda T, Corrado A, Iskandar G, Pelaia G, Abdalla K, Na-valesi P. High-flow nasal oxygen therapy in intensive care and anaesthesia. British journal of anaesthesia. 2018;120(1):18-27.
Tsolakoglou I, Sakkou A, Giannoulakis A, Stergiannis P, Karathanasi E, Intas G. Use of high-flow nasal cannula in patients with COVID-19: A retrospective study. Health & Research Journal. 2023; 9(1): 5-12.
Ospina-Tascón GA, Calderón-Tapia LE, García AF, Zarama V, Gómez-Álvarez F, Álvarez-Saa T, et al. Effect of High-Flow Oxygen Therapy vs Conventional Oxygen Therapy on Invasive Mechanical Ventilation and Clinical Recovery in Patients With Severe COVID-19: A Randomized Clinical Tri-al. JAMA. 2021;326(21):2161-71.
Bonnet N, Martin O, Boubaya M, Levy V, Ebstein N, Karou-bi P, et al. High flow nasal oxygen therapy to avoid inva-sive mechanical ventilation in SARS-CoV-2 pneumonia: a retrospective study. Annals of Intensive Care. 2021;11(1).
Montiel V, Robert A, Robert A, Nabaoui A, Marie T, Mestre NM, Guillaume M, Laterre PF, Wittebole X. Surgical mask on top of high-flow nasal cannula improves oxygenation in critically ill COVID-19 patients with hypoxemic respirato-ry failure. Annals of intensive care. 2020;10: 1-7.
Díaz-Lobato S, Perales JC, Iñigo JA, Alises SM, Segovia B, Escalier N. Things to keep in mind in high flow therapy: as usual the devil is in the detail. Int J Crit Care Emerg Med. 2018;4(2):1-8.
Mauri T, Galazzi A, Binda F, Masciopinto L, Corcione N, Carlesso E, Lazzeri M, Spinelli E, Tubiolo D, Volta CA, Ada-mini I. Impact of flow and temperature on patient comfort during respiratory support by high-flow nasal cannula. Critical Care. 2018;22(1): 1-8.